Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DWP 17061

X
Drug Profile

DWP 17061

Alternative Names: DWP-17061; iN1011-N17

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewoong Pharmaceutical
  • Developer Daewoong Pharmaceutical; iN Therapeutics
  • Class Analgesics
  • Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Musculoskeletal pain; Postherpetic neuralgia

Most Recent Events

  • 18 Nov 2023 DWP 17061 is still in phase I trial for Musculoskeletal pain (In volunteers) in Australia (PO, Capsule) (NCT05496205) (ACTRN12620001253998)
  • 08 Oct 2023 iN Therapeutics completes a phase I trial in Musculoskeletal pain (In volunteers) in Australia (PO, Capsule) (NCT05496205) (ACTRN12620001253998)
  • 11 Nov 2022 Phase-I clinical trials in Postherpetic neuralgia in Australia (PO) (NCT06218784)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top